Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9702875
SERIAL NO

14186285

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUTE GUSTAVE-ROUSSY39 RUECAMILLE DESMOULINS VILLEJUIF 94800

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Friboulet, Luc Le Havre, FR 2 5
Olaussen, Ken Paris, FR 3 6
Soria, Jean-Charles Paris, FR 15 47

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 11, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 11, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00